In the current study, we aimed to assess the efficacy of different Sofosbuvir (SOF)-based antiviral regimens available in Egypt in the treatment of Pegylated interferon/Ribavirin (PEG-INF/RBV)-experienced chronic hepatitis C virus (HCV) patients. Two hundred fifty-eight patients experienced with PEG-INF/RBV, and 1,283 naive patients were included in the study. The patients received one of the following 3 regimens for 12 weeks; PEG-INF/SOF, Simeprevir/SOF (SIM/SOF), and Daclatasvir/SOF (DCV/SOF). The endpoint was a sustained virological response 12 weeks (SVR12) after the end of the treatment. SVR12, treatment failure, and relapse were assessed. Moreover, predictors of SVR12 were analyzed. The mean age of treatment-experienced and treatment-naive patients was 51.11 ± 5.84 years and 50.04 ± 5.97 years, respectively. Treatment-experienced patients included 132 (51.16%) males and 126 (48.83%) females. Treatment-naive patients included 709 (55.26%) males and 574 (44.73%) females. The SVR12, treatment failure and treatment relapse rates in treatment-experienced versus treatment-naive patients were 91.1% versus 96.8%, 0.8% versus 0.9%, and 8.9% versus 2.7%, respectively. The SIM/SOF regimen provoked a ubiquitous high SVR12 in both treatment-experienced and -naive patients. A SIM/SOF regimen provokes the highest SVR12 in PEG-INF/RBV-experienced chronic HCV patients. Retreatment with PEG-INF/SOF in PEG-INF/RBV-experienced chronic HCV patients has a high probability of treatment failure.

中文翻译：

---

对聚乙二醇干扰素和利巴韦林双重疗法无反应的埃及慢性丙型肝炎患者的再治疗。

在本研究中，我们旨在评估埃及可用的不同基于Sofosbuvir（SOF）的抗病毒方案在治疗聚乙二醇化干扰素/利巴韦林（PEG-INF / RBV）所经历的慢性丙型肝炎病毒（HCV）患者中的疗效。这项研究包括了258名患有PEG-INF / RBV的患者和1,283名未接受过治疗的患者。患者接受以下3种治疗方案之一治疗12周。PEG-INF / SOF，Simeprevir / SOF（SIM / SOF）和Daclatasvir / SOF（DCV / SOF）。终点是治疗结束后12周（SVR12）的持续病毒学应答。评估SVR12，治疗失败和复发。此外，分析了SVR12的预测因子。有治疗经验和未经治疗的患者的平均年龄分别为51.11±5.84岁和50.04±5.97岁。有治疗经验的患者包括132名（51.16％）男性和126名（48.83％）女性。未经治疗的患者包括709位（55.26％）男性和574位（44.73％）女性。经历过治疗和未经治疗的患者的SVR12，治疗失败和复发率分别为91.1％对96.8％，0.8％对0.9％和8.9％对2.7％。SIM / SOF方案在有治疗经验的患者和未接受过治疗的患者中均引起普遍存在的高SVR12。SIM / SOF方案在PEG-INF / RBV经历的慢性HCV患者中激发出最高的SVR12。在有PEG-INF / RBV经验的慢性HCV患者中，用PEG-INF / SOF进行再治疗的治疗失败的可能性很高。经历过治疗和未经治疗的患者的治疗失败率和治疗复发率分别为91.1％对96.8％，0.8％对0.9％和8.9％对2.7％。SIM / SOF方案在有治疗经验的患者和未接受过治疗的患者中均引起普遍存在的高SVR12。SIM / SOF方案在PEG-INF / RBV经历的慢性HCV患者中激发出最高的SVR12。在有PEG-INF / RBV经验的慢性HCV患者中，用PEG-INF / SOF进行再治疗的治疗失败的可能性很高。经历过治疗和未经治疗的患者的治疗失败率和治疗复发率分别为91.1％对96.8％，0.8％对0.9％和8.9％对2.7％。SIM / SOF方案在有治疗经验的患者和未接受过治疗的患者中均引起普遍存在的高SVR12。SIM / SOF方案在PEG-INF / RBV经历的慢性HCV患者中激发出最高的SVR12。在有PEG-INF / RBV经验的慢性HCV患者中，用PEG-INF / SOF进行再治疗的治疗失败的可能性很高。